Vaccine (DNA plasmid) · Immune activation, directed at MERS-CoV spike protein · developed by INOVIO PHARMACEUTICALS
INO-4700 is a plasmid DNA vaccine administered intradermally. It is designed to elicit immune responses against MERS-CoV and is studied in Middle East Respiratory Syndrome Coronavirus infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04588428 | Phase 2 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | Completed | INO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.
See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INO catalysts and pipeline →